A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy

Mayo Clinic Proceedings

Volumn 85, Issue 6, 2010, Pages 538-550

  Bostwick, J Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; DESVENLAFAXINE; DIPHENHYDRAMINE; DOXEPIN; DOXYLAMINE; DULOXETINE; ESCITALOPRAM; ESTAZOLAM; ESZOPICLONE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANOREXIA; ANXIETY; APPETITE DISORDER; BLURRED VISION; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; HEALTH SURVEY; HUMAN; HYPOTENSION; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; NERVOUSNESS; NEUROPATHIC PAIN; PATIENT COMPLIANCE; PATIENT REFERRAL; PRESCRIPTION; PRIMARY MEDICAL CARE; PRURITUS; PSYCHOTHERAPY; REVIEW; SCREENING TEST; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; TREMOR; URINARY TRACT DISEASE; WATCHFUL WAITING; WEIGHT GAIN; XEROSTOMIA;

EID: 77952961871     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0565     Document Type: Review

References (88)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. (Pubitemid 37432885)
2. Williams JW Jr. Competing demands: does care for depression fit in primary care? J Gen Intern Med. 1998;13(2):137-139.
3. Nichols GA, Brown JB. Following depression in primary care: do family practice physicians ask about depression at different rates than internal medicine physicians? Arch Fam Med. 2000;9(5):478-482.
4. Dietrich AJ, Oxman TE, Williams JW Jr. Treatment of depression by mental health specialists and primary care physicians [letter]. JAMA. 2003;290(15):1991.
5. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008; 358(1):55-68.
6. Gelenberg AJ, Hopkins HS. Assessing and treating depression in primary care medicine. Am J Med. 2007;120(2):105-108. (Pubitemid 46175776)
7. Timonen M, Liukkonen T. Management of depression in adults. BMJ. 2008;336(7641):435-439.
8. American Psychiatric Association. Quick Reference to the Diagnostic Criteria From DSM-IV-TR®. Arlington, VA: American Psychiatric Association; 2000:167-208, 285-286.
9. Vuorilehto M, Melartin T, Isometsa E. Depressive disorders in primary care: recurrent, chronic, and co-morbid. Psychol Med. 2005;35(5):673-682. (Pubitemid 40716431)
10. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression: two questions are as good as many. J Gen Intern Med. 1997;12(7):439-445. (Pubitemid 27300561)
11. Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ. 2003; 327(7424):1144-1146. (Pubitemid 37421811)
12. Williams JW Jr, Noel PH, Cordes JA, Ramirez G, Pignone M. Is this patient clinically depressed? JAMA. 2002;287(9):1160-1170.
13. Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect depression in primary care? a pooled analysis and meta-analysis of 22 studies. Br J Gen Pract. 2007;57(535):144-151.
14. Ackermann RT, Williams JW Jr. Rational treatment choices for non-major depressions in primary care: an evidence-based review. J Gen Intern Med. 2002;17(4):293-301.
15. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
16. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65(5):513-520. (Pubitemid 351645047)
17. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609-619.
18. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289(1):56-64. (Pubitemid 36026278)
19. Zimmerman M, Posternak MA, Attiullah N, et al. Why isn't bupropion the most frequently prescribed antidepressant? J Clin Psychiatry. 2005; 66(5):603-610.
20. Mann JJ. The medical management of depression. N Engl J Med. 2005; 353(17):1819-1834.
21. Adams SM, Miller KE, Zylstra RG. Pharmacologic management of adult depression. Am Fam Physician. 2008;77(6):785-792.
22. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.
23. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469-473.
24. Rapaport MH. Future drugs for the treatment of depression: the need to look beyond monoamine systems. CNS Spectr. 2009;14(3)(suppl 5):14-16.
25. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180(3):305-313.
26. Maurer D, Colt R. An evidence-based approach to the management of depression. Prim Care. 2006;33(4):923-941, vii.
27. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc. 2001; 76(5):511-527.
28. Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132(9):743-756. (Pubitemid 30244176)
29. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-750.
30. Mulrow CD, Williams JW Jr, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med. 2000; 108(1):54-64. (Pubitemid 30058278)
31. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998;159(10):1245-1252. (Pubitemid 28554501)
32. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343(26):1942-1950.
33. Woolf AD, Erdman AR, Nelson LS, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(3):203-233.
34. Looper KJ. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics. 2007;48(1):1-9.
35. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288(11):1403-1409.
36. Bostwick JM. Do SSRIs cause suicide in children? the evidence is underwhelming. J Clin Psychol. 2006;62(2):235-241.
37. Maixner SM, Greden JF. Extended antidepressant maintenance and discontinuation syndromes. Depress Anxiety. 1998;8(suppl 1):43-53.
38. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997;58(suppl 7):37-40.
39. Papadopoulos S, Cook AM. You can withdraw from that? the effects of abrupt discontinuation of medications. Orthopedics. 2006;29(5):413-417. (Pubitemid 43918605)
40. Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci. 2008;10(4):409-418.
41. Marks DM, Park MH, Ham BJ, et al. Paroxetine: safety and tolerability issues. Expert Opin Drug Saf. 2008;7(6):783-794.
42. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet. 2009;373(9665):746-758.
43. Giuliano F, Hellstrom WJ. The pharmacological treatment of premature ejaculation. BJU Int. 2008;102(6):668-675.
44. Richelson E. Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc. 1994;69(11):1069-1081.
45. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69(suppl E1):8-13.
46. Beasley CM Jr, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol. 1992; 12(5):328-333.
47. Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? a meta-analytic study. J Affect Disord. 2001;65(2):173-177.
48. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75-85.
49. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med. 2008;28(4):619-626.
50. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002;36(10): 1577-1589.
51. Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008;13(12):1027-1038.
52. Silber MH. Clinical practice; chronic insomnia. N Engl J Med. 2005; 353(8):803-810.
53. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052-1060. (Pubitemid 43849658)
54. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555-1561. (Pubitemid 350036981)
55. Janowsky D, Curtis G, Zisook S, Kuhn K, Resovsky K, Le Winter M. Trazodone-aggravated ventricular arrhythmias. J Clin Psychopharmacol. 1983; 3(6):372-376.
56. Barrnett J, Frances A, Kocsis J, Brown R, Mann JJ. Peripheral edema associated with trazodone: a report of ten cases. J Clin Psychopharmacol. 1985;5(3):161-164. (Pubitemid 15077507)
57. Service JA, Waring WS. QT prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila). 2008;46(1):71-73.
58. Chung KJ, Wang YC, Liu BM, Supernaw RB. Management of ventricular dysrhythmia secondary to trazodone overdose. J Emerg Med. 2008; 35(2):171-174.
59. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60(suppl 17):28-31.
60. Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 2002;17(suppl 1):S37-S41.
61. Wiegand MH. Antidepressants for the treatment of insomnia: a suitable approach? Drugs. 2008;68(17):2411-2417.
62. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62(suppl 3):10-21.
63. Labbate LA. Psychotropics and sexual dysfunction: the evidence and treatments. Adv Psychosom Med. 2008;29:107-130.
64. Segraves RT. Sexual dysfunction associated with antidepressant therapy. Urol Clin North Am. 2007;34(4):575-579, vii.
65. Angulo J, Peiro C, Sanchez-Ferrer CF, et al. Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Br J Pharmacol. 2001;134(6):1190-1194. (Pubitemid 33097248)
66. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300(4):395-404. (Pubitemid 352040251)
67. Fava M, Rush AJ, Thase ME, et al. 15 Years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106-113. (Pubitemid 41783226)
68. DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother. 2007;41(7):1201-1211.
69. Corona G, Ricca V, Bandini E, et al. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med. 2009;6(5):1259-1269.
70. Harvey BH, Bouwer CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol. 2000; 23(2):90-97. (Pubitemid 30212219)
71. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment: mechanisms and management. Drug Saf. 1996;14(5):329-342.
72. Malone M. Medications associated with weight gain. Ann Pharmacother. 2005;39(12):2046-2055.
73. Jensen GL. Drug-induced hyperphagia: what can we learn from psychiatric medications? JPEN J Parenter Enteral Nutr. 2008;32(5):578-581.
74. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007; 100(7):395-404.
75. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry. 2001;62(4):256-260. (Pubitemid 32428764)
76. Baldwin DS, Reines EH, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother. 2007; 41(10):1583-1592. (Pubitemid 47485624)
77. Nelson JC, Lu Pritchett Y, Martynov O, Yu JY, Mallinckrodt CH, Detke MJ. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry. 2006;8(4):212-219.
78. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61 (suppl 11):37-41.
79. Jefferson JW. Bupropion extended-release for depressive disorders. Expert Rev Neurother. 2008;8(5):715-722.
80. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998;59(7):366-373.
81. Markowitz JC. When should psychotherapy be the treatment of choice for major depressive disorder? Curr Psychiatry Rep. 2008;10(6):452-457.
82. Scott J. Treatment of chronic depression. N Engl J Med. 2000;342(20): 1518-1520.
83. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000; 342(20):1462-1470.
84. Manber R, Kraemer HC, Arnow BA, et al. Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. J Consult Clin Psychol. 2008;76(3):459-467.
85. Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry. 2004;161(7): 1285-1289.
86. Unutzer J. Clinical practice: late-life depression. N Engl J Med. 2007; 357(22):2269-2276.
87. Takeshima M, Kitamura T, Kitamura M, et al. Impact of depressive mixed state in an emergency psychiatry setting: a marker of bipolar disorder and a possible risk factor for emergency hospitalization. J Affect Disord. 2008;111(1):52-60.
88. Demyttenaere K, Jaspers L. Review: bupropion and SSRI-induced side effects. J Psychopharmacol. 2008;22(7):792-804.